The Lenacapavir Partnership and the Evolution of U.S. Foreign Assistance | The Futures Summit

In September 2025, the U.S. Department of State, Gilead Sciences, and the Global Fund to Fight AIDS, Tuberculosis and Malaria announced a novel partnership to procure and deliver lenacapavir—a groundbreaking twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV prevention—to up to two million people over next three years.  On Tuesday, April 14, the leadership of these three entities convened to discuss the partnership now that doses have begun to arrive in country and have been delivered. Katherine E. Bliss, Director of Immunizations and Health Systems Resilience and Senior Fellow with the CSIS Global Health Policy Center moderated the conversation with Jeremy P. Lewin, Senior Official for the Office of the Under Secretary for Foreign Assistance, Humanitarian Affairs, and Religious Freedom at the U.S. Department of State; Daniel O’Day, Chairman and CEO of Gilead Sciences; and Peter Sands, Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria.  Together they examined how this deal fits into a renewed U.S. strategy for foreign assistance focused on big bets and advancing American innovations around the world, what challenges lie on the horizon as implementation unfolds, and what additional innovations may accelerate scaling this effort.